tradingkey.logo

IGM Biosciences Inc <IGMS.OQ> expected to post a loss of 74 cents a share - Earnings Preview

ReutersMar 3, 2025 12:08 PM
  • IGM Biosciences Inc IGMS.OQ IGMS.O is expected to show a fall in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024

  • The Mountain View California-based company is expected to report a 39.5% decrease in revenue to $393.75 thousand from $651 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for IGM Biosciences Inc is for a loss of 74 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00​, above​ its last closing price of $1.36. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.81

-0.80

-1.01

Missed

-26.2

Jun. 30 2024

-0.02

-0.04

-0.79

Missed

-1,991.1

Mar. 31 2024

-0.83

-0.83

-0.83

Met

0.2​

Dec. 31 2023

-0.96

-1.03

-1.01

Beat

2.2

​​Sep. 30 2023

-1.18

-1.21

-1.04

Beat

14.3

Jun. 30 2023

-1.44

-1.43

-1.43

Met

0.3​

Mar. 31 2023

-1.34

-1.36

-1.33

Beat

2.5

Dec. 31 2022

-1.25

-1.19

Beat

4.5

This summary was machine generated March 3 at 12:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI